Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Increasing RNAi efficiency through single nucleotide mismatches
US11208653B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11208653-B2 |
| Application number | US-201716097179-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 27, 2017 |
| Priority date | Apr 27, 2016 |
| Publication date | Dec 28, 2021 |
| Grant date | Dec 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and compositions for increasing RNAi efficiency through single nucleotide mismatches.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a mammal suffering from a condition, the method comprising administering to the mammal a therapeutically effective amount of an siRNA targeted to a target gene having a target sequence, wherein the siRNA comprises a guide sequence having at least one mismatch with respect to the target sequence, wherein the guide sequence mismatch with respect to the target sequence is located at guide position 6 of the guide sequence and is a G-G mismatch. 2. The method of claim 1 , wherein the siRNA is administered parenterally. 3. The method of claim 1 , wherein the siRNA is administered intravenously. 4. The method of claim 1 , wherein the siRNA is administered by bolus injection into a target organ or tissue. 5. The method of claim 1 , wherein the siRNA is administered intraperitoneally. 6. The method of claim 1 , wherein the siRNA is administered subcutaneously. 7. The method of claim 1 , wherein the mammal is a human.
Assignees
Inventors
Classifications
interfering nucleic acids [NA] · CPC title
- C12N15/111Primary
General methods applicable to biologically active non-coding nucleic acids · CPC title
- C12N15/113Primary
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
Methods for regulating/modulating their activity · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11208653B2 cover?
- Methods and compositions for increasing RNAi efficiency through single nucleotide mismatches.
- Who is the assignee on this patent?
- Whitehead Inst Biomedical Res
- What technology area does this patent fall under?
- Primary CPC classification C12N15/111. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).